Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecobalamin prophylaxis for capecitabine-induced hand-foot syndrome in breast cancer
ChiCTR2000029145Phase 4Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jan 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of mecobalamin in breast cancer (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Incidence rate of hand-foot syndrome above grade 2. Started Jan 2020; status: recruiting.
02
Drugs
mecobalamin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2000029145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029145.